PPP1R1A

Summary

PPP1R1A (protein phosphatase 1 regulatory inhibitor subunit 1A, HGNC:9286) is a protein-coding gene on chromosome 12q13.2, encoding Protein phosphatase 1 regulatory subunit 1A (Q13522). Inhibitor of protein-phosphatase 1.

Predicted to enable protein serine/threonine phosphatase inhibitor activity. Predicted to be involved in intracellular signal transduction. Predicted to be active in cytoplasm.

Source: NCBI Gene 5502 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 32 total
• MANE Select transcript: NM_006741

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9286
Approved symbol	PPP1R1A
Name	protein phosphatase 1 regulatory inhibitor subunit 1A
Location	12q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000135447
Ensembl biotype	protein_coding
OMIM	613246
Entrez	5502

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 nonsense_mediated_decay

ENST00000257905, ENST00000547431, ENST00000547826, ENST00000553113, ENST00000854646, ENST00000854647, ENST00000854648, ENST00000968383

RefSeq mRNA: 1 — MANE Select: NM_006741 NM_006741

CCDS: CCDS44912

Canonical transcript exons

ENST00000257905 — 7 exons

Exon	Start	End
ENSE00000920062	54582732	54582795
ENSE00001147254	54588405	54588659
ENSE00001532225	54579246	54580392
ENSE00003301465	54583211	54583248
ENSE00003357522	54584260	54584320
ENSE00003503573	54581976	54582131
ENSE00003595669	54580944	54581050

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 99.65.

FANTOM5 (CAGE): breadth broad, TPM avg 20.1124 / max 1217.8638, expressed in 503 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
131363	12.4198	483
131362	6.7505	419
131361	0.4808	181
131364	0.3919	134
131366	0.0424	18
131365	0.0269	15

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
triceps brachii	UBERON:0001509	99.65	gold quality
diaphragm	UBERON:0001103	99.47	gold quality
hindlimb stylopod muscle	UBERON:0004252	99.41	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	99.35	gold quality
gastrocnemius	UBERON:0001388	99.23	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	99.18	gold quality
gluteal muscle	UBERON:0002000	99.10	gold quality
vastus lateralis	UBERON:0001379	99.03	gold quality
biceps brachii	UBERON:0001507	99.01	gold quality
skeletal muscle tissue	UBERON:0001134	98.99	gold quality
body of tongue	UBERON:0011876	98.84	gold quality
quadriceps femoris	UBERON:0001377	98.79	gold quality
renal medulla	UBERON:0000362	98.70	gold quality
caudate nucleus	UBERON:0001873	98.34	gold quality
putamen	UBERON:0001874	98.32	gold quality
type B pancreatic cell	CL:0000169	98.23	gold quality
islet of Langerhans	UBERON:0000006	98.19	gold quality
muscle organ	UBERON:0001630	98.18	gold quality
muscle of leg	UBERON:0001383	97.86	gold quality
middle frontal gyrus	UBERON:0002702	97.76	gold quality
apex of heart	UBERON:0002098	97.71	gold quality
adipose tissue	UBERON:0001013	97.69	gold quality
lateral globus pallidus	UBERON:0002476	97.64	gold quality
subcutaneous adipose tissue	UBERON:0002190	97.61	gold quality
nucleus accumbens	UBERON:0001882	97.60	gold quality
deltoid	UBERON:0001476	97.49	gold quality
medial globus pallidus	UBERON:0002477	97.18	gold quality
right lobe of liver	UBERON:0001114	97.01	gold quality
right atrium auricular region	UBERON:0006631	96.82	gold quality
globus pallidus	UBERON:0001875	96.74	gold quality

Single-cell (SCXA)

Detected in 10 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-MTAB-11121	yes	848.57
E-MTAB-5061	yes	28.48
E-HCAD-31	yes	24.43
E-GEOD-81547	yes	16.39
E-MTAB-9388	yes	12.16
E-GEOD-83139	yes	9.00
E-HCAD-5	yes	8.68
E-ANND-3	yes	7.37
E-GEOD-81608	no	166.45
E-CURD-10	no	28.32

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

74 targeting PPP1R1A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-3609	99.52	69.89	2587

Literature-anchored findings (GeneRIF, showing 10)

• multiple domains in I-1 target cellular PP1 complexes, and I-1 has a role as a cellular regulator of eIF2alpha phosphorylation (PMID:15345721)
• G147D PPI-1 can attenuate responses of cardiomyocytes to beta-adrenergic agonists by decreasing PLN phosphorylation and therefore may contribute to deteriorated function in heart failure. (PMID:18192322)
• the human inhibitor-1 G147D polymorphism, found almost exclusively in blacks, may act as a modifier rather than risk factor in heart failure development (PMID:18698139)
• I-1 and sarco/endoplasmic reticulum Ca2+ -ATPase synergistically induce the vascular smooth muscle cell contractile phenotype. (PMID:24249716)
• These findings suggest that the human G109E inhibitor-1 variant impairs sarcoplasmic reticulum Ca-cycling and promotes arrhythmogenesis under stress conditions. (PMID:26455482)
• High PPP1R1A expression is associated with ewing sarcoma tumorigenesis and metastasis. (PMID:29059150)
• HOXC-AS3 is aberrantly overexpressed in breast cancers especially the HER2+ type. High expression of HOXC-AS3 has a relationship with poor clinical outcomes of breast cancer. HOXC-AS3 regulates cell invasion and migration both in vitro and in vivo. Results demonstrated that miR-3922-5p was a direct target of HOXC-AS3, and PPP1R1A was a target of miR-3922-5p in breast cancer. (PMID:31797701)
• The MafA-target gene PPP1R1A regulates GLP1R-mediated amplification of glucose-stimulated insulin secretion in beta-cells. (PMID:33631146)
• Exploring prognostic value and regulation network of PPP1R1A in hepatocellular carcinoma. (PMID:36018458)
• Unraveling the significance of PPP1R1A gene in pancreatic beta-cell function: A study in INS-1 cells and human pancreatic islets. (PMID:38574885)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ppp1r1a	ENSMUSG00000022490
rattus_norvegicus	Ppp1r1a	ENSRNOG00000036827

Paralogs (2): PPP1R1B (ENSG00000131771), PPP1R1C (ENSG00000150722)

Protein

Protein identifiers

Protein phosphatase 1 regulatory subunit 1A — Q13522 (reviewed: Q13522)

Alternative names: Protein phosphatase inhibitor 1

All UniProt accessions (4): Q13522, F8VR76, H0YIU4, R4GMQ8

UniProt curated annotations — full annotation on UniProt →

Function. Inhibitor of protein-phosphatase 1. This protein may be important in hormonal control of glycogen metabolism. Hormones that elevate intracellular cAMP increase I-1 activity in many tissues. I-1 activation may impose cAMP control over proteins that are not directly phosphorylated by PKA. Following a rise in intracellular calcium, I-1 is inactivated by calcineurin (or PP2B). Does not inhibit type-2 phosphatases.

Subunit / interactions. Interacts with PPP1R15A.

Post-translational modifications. Phosphorylation of Thr-35 is required for activity.

Similarity. Belongs to the protein phosphatase inhibitor 1 family.

RefSeq proteins (1): NP_006732* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008466	PPP1R1A/B/C	Family

Pfam: PF05395

UniProt features (19 total): modified residue 6, region of interest 4, sequence variant 2, mutagenesis site 2, sequence conflict 2, compositionally biased region 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13522-F1	67.33	0.09

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 46, 47, 67, 1, 35, 43

Mutagenesis-validated functional residues (2):

Position	Phenotype
35	no activity.
35	1000-fold reduction in activity, inhibits equally pp1 and pp2a.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 122 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, MORF_MSH3, MORF_BRCA1, SMID_BREAST_CANCER_RELAPSE_IN_LIVER_UP, SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN, MORF_RAD51L3, XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, WEI_MYCN_TARGETS_WITH_E_BOX, BLALOCK_ALZHEIMERS_DISEASE_UP, CAIRO_HEPATOBLASTOMA_DN, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN, NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN, DOUGLAS_BMI1_TARGETS_UP

GO Biological Process (3): glycogen metabolic process (GO:0005977), intracellular signal transduction (GO:0035556), signal transduction (GO:0007165)

GO Molecular Function (3): protein serine/threonine phosphatase inhibitor activity (GO:0004865), protein phosphatase inhibitor activity (GO:0004864), protein binding (GO:0005515)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular anatomical structure	2
energy reserve metabolic process	1
glucan metabolic process	1
signal transduction	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
protein serine/threonine phosphatase activity	1
protein phosphatase inhibitor activity	1
phosphoprotein phosphatase activity	1
phosphatase inhibitor activity	1
protein phosphatase regulator activity	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

794 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPP1R1A	PPP1R2	P41236	887
PPP1R1A	PPP1CC	P36873	764
PPP1R1A	PPP1R3A	Q16821	669
PPP1R1A	PRKCI	P41743	649
PPP1R1A	PPP1CA	P08129	617
PPP1R1A	PPP1CB	P37140	607
PPP1R1A	CSRP3	P50461	567
PPP1R1A	GYS1	P13807	543
PPP1R1A	AKAP7	O43687	540
PPP1R1A	PRKCA	P17252	477
PPP1R1A	LRATD1	Q96KN4	467
PPP1R1A	PPP2CA	P05323	463
PPP1R1A	PPP1R15A	O75807	458
PPP1R1A	NAP1L2	Q9ULW6	427
PPP1R1A	PNPLA4	P41247	425

IntAct

20 interactions, top by confidence:

A	B	Type	Score
SPEM1	PPP1R1A	psi-mi:“MI:0915”(physical association)	0.560
RRAGA	NPC2	psi-mi:“MI:0914”(association)	0.530
SLC25A11	POTEI	psi-mi:“MI:0914”(association)	0.530
PPP1R1A	ACTA1	psi-mi:“MI:0914”(association)	0.530
PPP1R1A	PPP1R15A	psi-mi:“MI:0915”(physical association)	0.510
PPP1R15A	PPP1R1A	psi-mi:“MI:0915”(physical association)	0.510
PPP1R1A	GLC7	psi-mi:“MI:0915”(physical association)	0.370
FGL1	DNM1L	psi-mi:“MI:0914”(association)	0.350
ZPBP2	PROS1	psi-mi:“MI:0914”(association)	0.350
SLC25A11	YES1	psi-mi:“MI:0914”(association)	0.350
SPEM1	PRG2	psi-mi:“MI:0914”(association)	0.350
PPP1R1A	ACTA2	psi-mi:“MI:0914”(association)	0.350
PRMT6	TFCP2	psi-mi:“MI:0914”(association)	0.350
PRMT6	TP73	psi-mi:“MI:0914”(association)	0.350
ZPBP2	PPP1R1A	psi-mi:“MI:0914”(association)	0.350

BioGRID (33): PPP1R15A (Two-hybrid), PPP1R15A (Reconstituted Complex), PPP1CA (Reconstituted Complex), PPP1CB (Reconstituted Complex), PPP1CC (Reconstituted Complex), PPP1R15A (Affinity Capture-Western), PPP1R1A (Affinity Capture-MS), PPP1R1A (Affinity Capture-MS), PPP1R1A (Affinity Capture-MS), PPP1R1A (Affinity Capture-MS), PPP1R1A (Affinity Capture-MS), PPP1R1A (Affinity Capture-MS), PPP1R1A (Affinity Capture-MS), ACTA2 (Affinity Capture-MS), ACTA1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GUA9, A0A1B0GV96, A4IFJ0, B3DGJ2, O43687, O55074, O70139, O75167, P04370, P0C8S0, P0C913, P0C914, P0CD96, P19103, P27775, P49342, P61925, P61926, P62025, P63248, P63249, Q04758, Q13522, Q29026, Q3SX13, Q3T0A6, Q3ZB98, Q4VC05, Q5FVI4, Q5R6X9, Q64256, Q6P3A1, Q71U53, Q7M2N1, Q7YQJ3, Q7YQJ4, Q8N111, Q8R409, Q8TAD7, Q8WMS3

Diamond homologs: P01099, P07516, P19103, Q13522, Q29277, Q5R853, Q60829, Q6J4I0, Q8BKK4, Q8WMS3, Q8WVI7, Q9ERT9, Q9UD71

SIGNOR signaling

8 interactions.

A	Effect	B	Mechanism
PPP3CB	unknown	PPP1R1A	dephosphorylation
PPP3CC	unknown	PPP1R1A	dephosphorylation
PPP2CB	unknown	PPP1R1A	dephosphorylation
PPP2CA	unknown	PPP1R1A	dephosphorylation
PPP3CA	unknown	PPP1R1A	dephosphorylation
CDK5	unknown	PPP1R1A	phosphorylation
Calcineurin	unknown	PPP1R1A	dephosphorylation
PP2B	unknown	PPP1R1A	dephosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	21
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1287 predictions. Top by Δscore:

Variant	Effect	Δscore
12:54575628:GATAG:G	donor_gain	1.0000
12:54575985:A:AG	acceptor_gain	1.0000
12:54575985:ACT:A	acceptor_gain	1.0000
12:54575986:C:G	acceptor_gain	1.0000
12:54575987:T:A	acceptor_gain	1.0000
12:54575988:GCAGG:G	acceptor_loss	1.0000
12:54575990:A:AG	acceptor_gain	1.0000
12:54575990:AG:A	acceptor_gain	1.0000
12:54575991:G:GG	acceptor_gain	1.0000
12:54575991:GG:G	acceptor_gain	1.0000
12:54576099:AGG:A	donor_loss	1.0000
12:54576100:GGT:G	donor_loss	1.0000
12:54576101:G:GG	donor_gain	1.0000
12:54576102:T:G	donor_loss	1.0000
12:54576665:GAGAA:G	donor_gain	1.0000
12:54576682:G:GT	donor_gain	1.0000
12:54576687:A:T	donor_gain	1.0000
12:54576699:GTG:G	donor_gain	1.0000
12:54577212:T:G	acceptor_gain	1.0000
12:54577212:T:TA	acceptor_gain	1.0000
12:54577221:A:AG	acceptor_gain	1.0000
12:54577221:ACAG:A	acceptor_gain	1.0000
12:54577222:C:G	acceptor_gain	1.0000
12:54577223:A:AG	acceptor_gain	1.0000
12:54577223:AG:A	acceptor_gain	1.0000
12:54577224:G:GC	acceptor_gain	1.0000
12:54577224:GG:G	acceptor_gain	1.0000
12:54577224:GGC:G	acceptor_gain	1.0000
12:54577224:GGCA:G	acceptor_gain	1.0000
12:54577224:GGCAT:G	acceptor_gain	1.0000

AlphaMissense

1110 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:54588453:G:C	F12L	1.000
12:54588453:G:T	F12L	1.000
12:54588455:A:G	F12L	1.000
12:54584308:G:T	R33S	0.999
12:54584311:G:T	R32S	0.999
12:54584319:A:G	I29T	0.999
12:54588454:A:C	F12C	0.999
12:54588454:A:G	F12S	0.999
12:54588460:A:G	I10T	0.999
12:54584295:G:T	A37D	0.998
12:54584305:G:A	P34S	0.998
12:54588460:A:C	I10S	0.998
12:54584305:G:T	P34T	0.997
12:54584308:G:C	R33G	0.997
12:54584319:A:C	I29S	0.997
12:54584304:G:T	P34H	0.996
12:54584310:C:G	R32P	0.996
12:54584311:G:C	R32G	0.996
12:54588455:A:C	F12V	0.996
12:54588460:A:T	I10N	0.996
12:54584319:A:T	I29N	0.995
12:54588416:C:G	A25P	0.994
12:54588455:A:T	F12I	0.994
12:54584298:G:T	P36H	0.993
12:54584312:C:A	R31S	0.993
12:54584312:C:G	R31S	0.993
12:54584316:C:G	R30P	0.993
12:54584317:G:C	R30G	0.993
12:54584289:A:G	L39P	0.991
12:54588413:C:G	A26P	0.991

dbSNP variants (sampled 300 via entrez): RS1000213696 (12:54578918 T>A), RS1000269044 (12:54585543 C>T), RS1000689083 (12:54584381 C>A), RS1000883350 (12:54584796 C>A,T), RS1001010961 (12:54590335 A>AC), RS1001545188 (12:54585008 T>C), RS1001645081 (12:54581351 C>A,T), RS1001826802 (12:54585252 C>A,T), RS1002437358 (12:54585898 A>C,G), RS1002604772 (12:54589742 A>G), RS1002622049 (12:54589519 A>C), RS1003096630 (12:54589155 C>G), RS1003315632 (12:54582871 C>T), RS1003334727 (12:54588263 C>G,T), RS1003618226 (12:54588590 G>C,T)

Disease associations

OMIM: gene MIM:613246 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): rosette-forming glioneuronal tumor of fourth ventricule (MONDO:0016736)

Orphanet (1): Rosette-forming glioneuronal tumor (Orphanet:251975)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST008151_10	Waist circumference	6.000000e-06
GCST008157_23	Body fat mass	8.000000e-06
GCST008160_55	Waist circumference	6.000000e-06
GCST008162_15	Hip circumference	3.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

8 measured of 12 human assays (12 total across all organisms); most potent 8 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Calyculinamide A (18)	IC50	5 nM
C1/C34-Calyculin A (15)	IC50	9 nM
Des-N-methylcalyculin A (20)	IC50	11 nM
Calyculin A 21-acetate (13)	IC50	13 nM
Hemicalyculin A (5)	IC50	14 nM
Calyculin C (24)	IC50	29 nM
Calyculin J (14)	IC50	105 nM
Calyculin A (4)	IC50	112 nM

PubChem BioAssay actives

11 with measured affinity, of 15 total; 8 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(2R,3R,7R,8S)-2-[(1S,3S,5R,7E,9E,11E,13E)-15-amino-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyl-15-oxopentadeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[4-[[(2S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4-yl]prop-2-enyl]-7-hydroxy-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate	1799476: Inhibition Assay from Article 10.1016/S1074-5521(02)00118-7: “Insight into binding of calyculin A to protein phosphatase 1: isolation of hemicalyculin a and chemical transformation of calyculin A.”	ic50	0.0050	uM
[(2R,3R,7R,8S)-2-[(1S,3S,5R,7E,9E,11E,13E)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[4-[[(2S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4-yl]prop-2-enyl]-7-hydroxy-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate	1799476: Inhibition Assay from Article 10.1016/S1074-5521(02)00118-7: “Insight into binding of calyculin A to protein phosphatase 1: isolation of hemicalyculin a and chemical transformation of calyculin A.”	ic50	0.0082	uM
[(2R,3R,7R,8S)-2-[(1S,3S,5R,7E,9E,11E,13E)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-7-hydroxy-9-[(E)-3-[2-[4-[(2-hydroxyacetyl)amino]butan-2-yl]-1,3-oxazol-4-yl]prop-2-enyl]-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate	1799476: Inhibition Assay from Article 10.1016/S1074-5521(02)00118-7: “Insight into binding of calyculin A to protein phosphatase 1: isolation of hemicalyculin a and chemical transformation of calyculin A.”	ic50	0.0090	uM
[(2R,3R,7R,8S)-2-[(1S,3S,5R,7E,9E,11E,13E)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[4-[[(2S,4S)-2,3-dihydroxy-5-methoxy-4-(methylamino)pentanoyl]amino]butan-2-yl]-1,3-oxazol-4-yl]prop-2-enyl]-7-hydroxy-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate	1799476: Inhibition Assay from Article 10.1016/S1074-5521(02)00118-7: “Insight into binding of calyculin A to protein phosphatase 1: isolation of hemicalyculin a and chemical transformation of calyculin A.”	ic50	0.0110	uM
[(2R,3R,7R,8R)-2-[(1S,3S,5R,7E,9E,11E,13E)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[4-[[(2S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4-yl]prop-2-enyl]-4,4,8-trimethyl-3-phosphonooxy-1,10-dioxaspiro[4.5]decan-7-yl] acetate	1799476: Inhibition Assay from Article 10.1016/S1074-5521(02)00118-7: “Insight into binding of calyculin A to protein phosphatase 1: isolation of hemicalyculin a and chemical transformation of calyculin A.”	ic50	0.0130	uM
[(2R,3R,7R,8S)-2-[(1S,3S,5R,7E,9E,11E,13E)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-cyanoprop-2-enyl]-7-hydroxy-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate	1799476: Inhibition Assay from Article 10.1016/S1074-5521(02)00118-7: “Insight into binding of calyculin A to protein phosphatase 1: isolation of hemicalyculin a and chemical transformation of calyculin A.”	ic50	0.0140	uM
[(2R,3R,7R,8S)-2-[(1S,3S,5R,7E,9E,11E,13E)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[4-[[(2S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]pentan-2-yl]-1,3-oxazol-4-yl]prop-2-enyl]-7-hydroxy-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate	1799476: Inhibition Assay from Article 10.1016/S1074-5521(02)00118-7: “Insight into binding of calyculin A to protein phosphatase 1: isolation of hemicalyculin a and chemical transformation of calyculin A.”	ic50	0.0290	uM
[(2R,3R)-2-[(1S,3S)-4-[(3S,4R)-4-bromo-5-[(2E,4E,6E)-7-cyano-6-methylhepta-2,4,6-trien-2-yl]-3,5-dimethyloxolan-2-yl]-3-hydroxy-1-methoxypentyl]-5-[(E)-4-[2-[4-[[(2S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4-yl]but-3-enoxy]-5-[(2S)-2-hydroxybutyl]-4,4-dimethyloxolan-3-yl] dihydrogen phosphate	1799476: Inhibition Assay from Article 10.1016/S1074-5521(02)00118-7: “Insight into binding of calyculin A to protein phosphatase 1: isolation of hemicalyculin a and chemical transformation of calyculin A.”	ic50	0.1050	uM

CTD chemical–gene interactions

55 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	4
Valproic Acid	affects cotreatment, increases expression, affects expression	4
bisphenol A	affects cotreatment, increases methylation, increases expression	3
Acetaminophen	decreases expression, increases expression	3
Aflatoxin B1	affects expression, decreases expression, decreases methylation	3
mercuric bromide	affects cotreatment, decreases expression	2
Panobinostat	affects cotreatment, increases expression	2
Dexamethasone	increases expression, affects cotreatment	2
Estradiol	increases expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Triclosan	affects cotreatment, decreases expression	2
Cyclosporine	decreases expression, increases expression	2
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	increases expression	1
terbufos	increases methylation	1
trichostatin A	increases expression	1
sodium arsenite	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
entinostat	increases expression, affects cotreatment	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression, decreases expression	1
bisphenol S	decreases methylation	1
(+)-JQ1 compound	decreases expression	1
Rosiglitazone	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Troglitazone	increases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TF70	HAP1 PPP1R1A (-) 1	Cancer cell line	Male
CVCL_TF71	HAP1 PPP1R1A (-) 2	Cancer cell line	Male
CVCL_TF72	HAP1 PPP1R1A (-) 3	Cancer cell line	Male
CVCL_TF73	HAP1 PPP1R1A (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03975829	PHASE4	RECRUITING	Pediatric Long-Term Follow-up and Rollover Study